EXACT Sciences — Q2 2025 Earnings Presentation
21 slides from EXACT Sciences's earnings presentation, Aug 6, 2025
Slide 1: Second-quarter 2025 Earnings Call
Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. Second-quarter 2025 Earnings Call August 6, 2025 EXACT SCIENCES 1
Slide 2: Safe harbor and non-GAAP disclosures
Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are sub
Slide 3: Exact Sciences is a global leader in advanced cancer diagnostics with a differentiated platform
Exact Sciences is a global leader in advanced cancer diagnostics with a differentiated platform OUR FOOTPRINT OUR IMPACT & SCALE OUR CAPABILITIES 7,000+ 1.3M+ Proprietary scientific platform detects cancer earlier and accurately global team members test results in 2Q25 200K+ $811M Powerful commercia
Slide 4: Core revenue grew 16% in 2Q25
Core revenue grew 16% in 2Q25 Core revenue Screening revenue Precision Oncology core revenue $808M $697M +16% $628M $532M +18% $165M $179M +9% 2Q24 2Q25 2Q24 2Q25 2Q24 2Q25 Please refer to our second-quarter 2025 earnings release at exactsciences.com for discussion of non-GAAP financial measures and
Slide 5: Profitability continued to improve in 2Q25
Profitability continued to improve in 2Q25 Adjusted EBITDA Free cash flow Adjusted EBITDA margin $138M 17% +$28M +130 bps $46M $110M 16% $95M -$49M 2Q24 2Q25 2024 YTD 2025 YTD Please refer to our second-quarter 2025 earnings release at exactsciences.com for discussion of non-GAAP financial measures
Slide 6: Updated 2025 guidance
Updated 2025 guidance $ ∆ at Prior guidance August 6 update midpoint Total revenue $3.070 – 3.120B $3.130 – 3.170B +$55M Screening $2.390 – 2.425B $2.440 – 2.470B +$48M Precision Oncology $680 - 695M $690 - 700M +$8M Adj. EBITDA $425 - 455M $455 – 475M +$25M Exact Sciences guidance provided August 6
Slide 7: Multi-year productivity program plan will drive sustained growth and improve operating leverage
Multi-year productivity program plan will drive sustained growth and improve operating leverage Key drivers Reduce external spend $150M Restructure support functions annual run-rate cost savings by 2026 Accelerate the use of AI and automation EXACT SCIENCES 7
Slide 8: Cologuard has now been used to screen over 20M times
Cologuard® has now been used to screen over 20M times Cumulative completed Growth drivers Cologuard tests 20M+ New Cologuard patients Rescreens Rescreens 45-49 (recurring testing) age group 10M Cologuard PlusTM 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 YTD Source: Exact Sciences in
Slide 9: Exact Sciences is at the forefront in reducing colon cancer mortality
Exact Sciences is at the forefront in reducing colon cancer mortality Problem Solution Cologuard Plus, our leading CRC screening test 50M+ unscreened Advanced colorectal cancer screening blood test Americans Platform & infrastructure to drive adoption Source: American Cancer Society Cancer Facts & F
Slide 10: Exclusive access to a leading blood-based colorectal cancer screening test
Exclusive access to a leading blood-based colorectal cancer screening test OVERALL ADVACNED ADENOMA SPECIFICITY SENSITIVITY SENSITIVITY V1 81% 14% 90% Source: Shaukat A, Burke CA, Chan AT, et al. Clinical Validation of a Circulating Tumor DNA–Based Blood Test to Screen for Colorectal Cancer. JAMA. 2
Slide 11: Cancerguard screens for multiple types of cancer through a single blood draw
CancerguardTM screens for multiple types of cancer through a single blood draw Problem Solution Progress with Cancerguard Progress with multi-cancer early and upcoming detection milestones and upcoming milestones Published data showing 67% 14% sensitivity for 6 deadliest cancers Generate real-world
Slide 12: The Oncodetect test uses unique science to predict and detect cancer relapses earlier
The OncodetectTM test uses unique science to predict and detect cancer relapses earlier Now covered by Medicare for colorectal cancer patients EXACT SCIENCES 12
Slide 13: Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment
Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment EXACT SCIENCES 13
Slide 14: EXACT SCIENCES
EXACT SCIENCES 14
Slide 15: Condensed Consolidated Statements of Operations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Operations (Amounts in thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue $ 811,085 $ 699,264 $ 1,517,870 $ 1,336,788 Cost of sale
Slide 16: Condensed Consolidated Balance Sheets
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Balance Sheets (Amounts in thousands) December 31, June 30, 2025 2024 Assets Cash and cash equivalents $ 657,099 $ 600,889 Marketable securities 201,336 437,137 Accounts receivable, net 353,335 248,968 Invento
Slide 17: Reconciliation of Core Revenue
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of Core Revenue (Amounts in thousands) GAAP Three Months Ended June 30, 2025 2024 % Change Screening $ 628,481 $ 531,606 18 % Precision Oncology 182,604 167,658 9 % Total $ 811,085 $ 699,264 16 % Non-GAAP Three Months
Slide 18: EBITDA and Adjusted EBITDA Reconciliations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net loss $ (1,185) $ (15,808) $ (102,400) $ (126,036) Interest expense (income) 9,835 (111)
Slide 19: Reconciliation of U.S. GAAP to Non-GAAP Measures
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of U.S. GAAP to Non-GAAP Measures (Amounts in thousands) Three Months Ended June 30, 2025 Research & General & Development Sales & Marketing Administrative Income (Loss) from Net Income (Loss) Income Tax Benefit Net I
Slide 20: Reconciliation of U.S. GAAP to Non-GAAP Measures
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of U.S. GAAP to Non-GAAP Measures (Amounts in thousands) Three Months Ended June 30, 2024 Research & General & Development Sales & Marketing Administrative Income (Loss) from Net Income (Loss) Income Tax Benefit Net I
Slide 21: Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow (Amounts in thousands) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net cash provided by operating activities 89,017 1